Is leptomeningeal dissemination in oligodendroglioma predictable? Evidence from a scoping review
By
Hanna Veronika Salvotti
Francesco Brigo
Paolo Cipriano Cecchi
Davide Costazza
Vania Pirillo
Luca Zavatto
Francesco Erdini
Andreas Schwarz
Pier Paolo Berti
June 15, 2026
Clinical Scorecard: Can Leptomeningeal Dissemination in Oligodendroglioma Be Anticipated? Insights from a Scoping Review
At a Glance
Category Detail
Condition Key Mechanisms IDH mutation and 1p/19q co-deletion. Target Population Patients with histologically confirmed Oligodendroglioma. Care Setting
Key Highlights
LMD in ODG is rare. Mean age at LMD diagnosis is 43.1 years with male predominance. 85.7% of patients had WHO grade 3 ODG at LMD diagnosis. Median survival after LMD is 9.9 months. Guideline-Based Recommendations
Diagnosis
Monitor for symptoms of LMD in patients with ODG. Management
Current management is largely palliative. Monitoring & Follow-up
Long-term MRI surveillance in selected patients. Risks
LMD is associated with rapid neurological decline. Patient & Prescribing Data
Chemotherapy, radiotherapy, and surgery are utilized.
Clinical Best Practices
Consider MRI surveillance for patients at risk of LMD. Related Resources & Content
